Loading lessons…
Peptide learning paths
Learn peptides step by step
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
272lessons
8paths
0day streak
0%explored
Start your first lesson
Choose a learning path below or search the library. Progress saves in your browser.
Prefer timeline chaos? Peptide X Quiz · Literacy certify
Learning paths
Pick a track — progress rings update as you complete lessons.
6 lessons
10mResearchAdvanced
What the 2026 Sports Medicine Review Says About Peptide Therapies for Injuries
The latest sports medicine review is useful because it separates promising recovery biology from the human evidence gap and the antidoping risks.
9mPeptidesIntermediate
Injectable Peptides in Sports Medicine: What the Evidence and Antidoping Rules Actually Say
Sports medicine keeps pulling peptides into the conversation because recovery pressure is real. The hard part is separating promising biology from weak evidence, gray-market hype, and antidoping risk.
8mResearchAdvanced
Peptide Clinical Evidence in 2026: How to Separate Signal from Hype
Peptide research is moving fast. Here is how to read the evidence before turning a headline, mechanism, or social post into a protocol.
7mResearchAdvanced
The Multi-Peptide Stack: What 2026 Peer-Reviewed Science Actually Shows
Two 2026 peer-reviewed reviews in Sports Medicine and JAAOS now formally catalog BPC-157, TB-500, GHK-Cu, CJC-1295, and Ipamorelin stacks. Here is what the science actually shows — and where the gaps still are.
8mResearchAdvanced
BPC-157 Human Hamstring Trial: Why This Study Matters
BPC-157 finally has a registered human sports-injury study. The signal is important, but it is not proof yet. Here is how to read the trial without the hype.
8mResearchAdvanced
Peptide Therapy for Sports Injuries: What 2026 Evidence Really Shows
A new sports medicine review puts injury-recovery peptides in context. Some mechanisms are promising, but human evidence, safety data, and regulatory status still matter.
Also available at /blog for legacy links.